Potential of afatinib in the treatment of patients with HER2-positive breast cancer

Breast Cancer: Targets and Therapy

Volumn 4, Issue , 2012, Pages 131-137

  Geuna, Elena ^a   Montemurro, Filippo ^a,b,c   Aglietta, Massimo ^a,b,d   Valabrega, Giorgio ^a,b,d  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b Foundation of Piedmont Oncology   (Italy)

^c Unit of Investigative Clinical Oncology   (Italy)

^d University Medical School of Turin   (Italy)

Author keywords

Afatinib; Brain metastasis; Human epidermal growth factor receptor 2; Metastatic breast cancer; Monoclonal antibodies; Small molecule kinase inhibitors

Indexed keywords

AFATINIB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; LAPATINIB; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

ACNE; ADVANCED CANCER; APOPTOSIS; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRY SKIN; DYSPNEA; ENZYME ACTIVE SITE; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SKIN TOXICITY; SOLID TUMOR; THYROID CANCER; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER; VOMITING;

EID: 84869206583     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S25868     Document Type: Review

References (35)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505-516.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
3. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366: 109-119.
4. Blackwell et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in HER2- positive locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. J Clin Oncol 30, 2012 (suppl; abstr LBA1).
5. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124-1130.
6. Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2- positive breast cancer. J Clin Oncol. 2010;28:1301-1307.
7. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355: 2733-2743
8. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702-4711.
9. Miller et al. Phase IIB/III double-blind randomized trial of afatinib + best supportive care versus placebo + best supportive care in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX lung 1). Annals of Oncology 21 (Supplement 8).
10. Yamamoto N et al. A phase II trial of afatinib in patients with advanced non-small cell lung cancer previously treated with erlotib or gefitinib. J Clin Oncol 29: 2011 (suppl; abstr 7524).
11. Yang JC-H, Schuler MH, Yamamoto N, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. ASCO Meeting Abstracts. 2012;30:LBA7500.
12. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008;9:1336-1346.
13. Eskens FA, Mom CH, Planting AS, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98:80-85.
14. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28:3965-3972.
15. Ang J, et al. A phase I study of daily BIBW 2992, an irreversible EGR7HER2 dual kinase inhibitor, in combination with weekly paclitaxel. J Clin Oncol 27, 2009 (suppl; abstr e14541).
16. Vermorken JB, Machiels JH, Rottey S. Phase Ib study evaluating the combintion of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5FU (PF) in patients with advanced solid tumors. J Clin Oncol 28, 2010 (suppl; abstr e13521).
17. Hollebecque A et al. Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors. J Clin Oncol 30, 2012 (suppl; abstr 3104).
18. Senellart H, et al. Phase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors.
19. Senellart H, et al. Phase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors. J Clin Oncol 30, 2012 (suppl; abstr e13010).
20. Shaw H, Plummer R, Vidal L, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HeR2 receptoor tyrosine Kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2006;24(18S): Suppl 3027.
21. Lewis N, Marshall J, Amelsberg A, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2006;24(18S): Suppl 3091.
22. Hickish T, et al. Use of BIBW2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res 2009;69(24 Suppl):Abstract nr 5060.
23. Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133(3):1057-1065.
24. Harbeck N, et al. BIBW2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor for the treatment of patients with HER2- negative metastatic breast cancer after failure of no more than two prior chemotherapies. Cancer Res 2009;69(24 Suppl):Abstract nr 5062
25. Rimawi MF, Aleixo SB, Alarcon Rozas A, et al. A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). ASCO Meeting Abstracts. 2012; 30:606.
26. Gunzer K, et al. Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy. J Clin Oncol 28:15s, 2010 (suppl; abstr 1072).
27. Data from www.clinicaltrial.gov (last update July 2012).
28. Hickish T, Tseng LM, Mehta AO, et al. LUX-breast 2: Phase II, open- label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). ASCO Meeting Abstracts. 2012;30:TPS651.
29. Ocana A, Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev. 2009;35:685-691.
30. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15:1452-1459.
31. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18: 2349-2351.
32. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.
33. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633-640.
34. Chang JCN. TBCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2 overexpressing breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 505).
35. Holmes F. A. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol 29: 2011 (suppl; abstr 506).